Published in
American Association for the Advancement of Science, Science Translational Medicine, 483(11), 2019
DOI: 10.1126/scitranslmed.aaq1238
Links
Tools
ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism
Journal article published in 2019 by
David H. Peng 
,
Samrat T. Kundu ,
Jared J. Fradette ,
Lixia Diao ,
Pan Tong,
Jing Wang,
Pamela A. Villalobos,
Barbara Mino,
Yanan Yang,
Rosalba Minelli,
Michael D. Peoples ,
Timothy P. Heffernan ,
Ignacio I. Wistuba ,
Don L. Gibbons ,
Lauren A. Byers
and other authors.
,
Samrat T. Kundu ,
Jared J. Fradette ,
Lixia Diao ,
Pan Tong,
Jing Wang,
Pamela A. Villalobos,
Barbara Mino,
Yanan Yang,
Rosalba Minelli,
Michael D. Peoples ,
Timothy P. Heffernan ,
Ignacio I. Wistuba ,
Don L. Gibbons ,
Lauren A. Byers
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
Suppression of ZEB1 through miR-200 expression or HDAC inhibition with mocetinostat sensitizes resistant KRAS mutant lung cancers to MEK inhibition.